Jump Financial, LLC Affimed N.V. Transaction History

Jump Financial, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	SELL	$1.96 - $3.32 $243,236 - $412,012	-124,100 Reduced 89.8%	14,100 $29,000
Q2 2022 Aug 09, 2022	BUY	$2.27 - $4.86 $224,049 - $479,682	98,700 Added 249.87%	138,200 $383,000
Q1 2022 May 12, 2022	BUY	$3.69 - $5.65 $104,427 - $159,895	28,300 Added 252.68%	39,500 $173,000
Q4 2021 Feb 10, 2022	BUY	$5.37 - $7.07 $60,144 - $79,184	11,200 New	11,200 $62,000
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $489,359 - $663,373	-88,332 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$7.78 - $11.4 $176,076 - $258,004	22,632 Added 34.45%	88,332 $751,000
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $1,024 - $1,696	-200 Reduced 0.3%	65,700 $520,000
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $176,328 - $392,274	55,800 Added 552.48%	65,900 $384,000
Q3 2020 Nov 13, 2020	BUY	$3.26 - $4.73 $32,926 - $47,773	10,100 New	10,100 $34,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.